SCORE Emerging Adult Cannabis Use & Stress
Key facts
- Who runs it
- Medical University of South Carolina
- Where
- Charleston, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 148 people, planned
- Started
- 1 Nov 2023
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cannabidiol oral solution
- Placebo
- Record updated
- 5 November 2025
Who can take part
- Age
- 18 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments
- Meet DSM-5 criteria for CUD and report using cannabis at least five times weekly over the past month. While individuals may also meet criteria for other mild substance use disorders, they must identify cannabis as their primary substance
- Age 18-25
- BMI between 18-30 (to decrease variability in CBD response and in endocannabinoid system measures)
- AST, ALT, and total bilirubin within the laboratory reference range of normal
- Consent to alcohol abstinence for 12 hours prior to study visits, three days of cannabis abstinence as part of study procedures, and abstinence from all substances aside from cannabis, alcohol, and nicotine for the duration of the study
- Sexually active females of childbearing potential must agree to utilize an effective means of birth control
- Consent to random assignment to CBD versus placebo
Who cannot take part
- Current medications or supplements with clinically significant interactions with cannabidiol (per Lexicomp, this list includes Blasting, Doxorubicin, Mavacamten, Pazopanib, Sirolimus, Topotecan, Vincristine, Afatinib, Berotraslstat, Cilostazol, Citalopram, Colchicine, Digoxin, Lefamulin, Relugolix, Relugolix+Estradiol+Norethindrone, Rimegepant, Tizanidine, Ubrogepant, and Venetoclax in the categories of "avoid combination" or "consider therapy modification")
- Current severe substance use disorder other than cannabis
- Current unstable psychiatric or medical disorder that would interfere with safety, compromise data integrity, or preclude reliable participation
- History of hypersensitivity to CBD, sesame, or sesame products
- Females who are pregnant, nursing, or planning to become pregnant during the study
- Inability to comply with study procedures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 25 years old?
Where in United States
- Medical University of South CarolinaCharleston, United StatesContact: Sarah BourneTaking people
About the trial
What the trial wants to find out
The interface between cannabis use and stress is a particularly important focus for sex differences research in emerging adults. Given the dynamics at play in this critical stage when cannabis use is most prevalent, developmentally informed research is needed to guide tailored clinical interventions. This study will apply rigorous and innovative methods to elucidate sex differences in the nexus of cannabis use and stress among emerging adults with cannabis use disorder to guide the development of tailored treatments.
The 2 groups in the trial
- cannabidiol 800 mgTreatment being tested
Cannabidiol 800 mg will be administered orally once in the laboratory prior to a stress induction paradigm.
Treatment: Cannabidiol oral solution
- placeboPlacebo, for comparison
Placebo (formulated to appear identical to active condition) administered orally once in the laboratory prior to a stress induction paradigm.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Sex Differences in the Interface Between Cannabis Use and Stress Among Emerging Adults
- Fit questions
- Built from NCT05885542, who can take part
- Record updated
- 5 November 2025